Photo Credit: gorodenkoff
The following is a summary of “Robotic laparoendoscopic single-site ultrasound-guided renal artery balloon catheter occluded hybrid partial nephrectomy (LESS-HPN): a prospective pilot study,” published in the February 2025 issue of BMC Urology by Shi et al.
Researchers conducted a retrospective study to investigate a novel intracorporeal minimally invasive procedure for robot-assisted laparoendoscopic single-site partial nephrectomy.
They performed robotic laparoendoscopic single-site ultrasound-guided renal artery balloon catheter occluded hybrid partial nephrectomy (LESS-HPN). A Freeport for LESS was inserted through a 4.5–5.0 cm skin incision. A Fogarty balloon catheter was used to occlude the renal artery or its branch instead of the traditional clamping technique. Tumor resection and wound suturing were then performed as routine steps.
The results showed that 10 patients with T1 stage renal tumors underwent successful LESS-HPN from March to July 2023, with no conversions to renal artery clamping or additional ports. The mean operative time was 103.3 ± 11.1 min, including 21.0 ± 2.7 min of warm ischemia time. The mean estimated blood loss was 42.0 ± 22.5 ml. Tumors located posteriorly had shorter operative times than those located anteriorly (P = 0.041). The occlusion of the main renal artery, branch arteries, and accessory renal artery was achieved in 7, 2, and 1 case, respectively. No recurrence, metastasis, or death was observed during a median follow-up of 10.5 months.
Investigators found LESS-HPN to be a safe and feasible alternative for intracorporeal minimal invasiveness in renal tumors. No recurrence, metastasis, or death was observed during follow-up.
Source: doi.org/10.1186/s12894-025-01711-z
